These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 34163157)

  • 1. Mepolizumab for Eosinophil-Associated COPD: Analysis of METREX and METREO.
    Pavord ID; Chapman KR; Bafadhel M; Sciurba FC; Bradford ES; Schweiker Harris S; Mayer B; Rubin DB; Yancey SW; Paggiaro P
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1755-1770. PubMed ID: 34163157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.
    Pavord ID; Chanez P; Criner GJ; Kerstjens HAM; Korn S; Lugogo N; Martinot JB; Sagara H; Albers FC; Bradford ES; Harris SS; Mayer B; Rubin DB; Yancey SW; Sciurba FC
    N Engl J Med; 2017 Oct; 377(17):1613-1629. PubMed ID: 28893134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
    Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No genetic associations with mepolizumab efficacy in COPD with peripheral blood eosinophilia.
    Condreay LD; Gao C; Bradford E; Yancey SW; Ghosh S
    Respir Med; 2019 Aug; 155():26-28. PubMed ID: 31295674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
    Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
    Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma.
    Albers FC; Licskai C; Chanez P; Bratton DJ; Bradford ES; Yancey SW; Kwon N; Quirce S
    Respir Med; 2019 Nov; 159():105806. PubMed ID: 31751853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.
    Criner GJ; Celli BR; Singh D; Agusti A; Papi A; Jison M; Makulova N; Shih VH; Brooks L; Barker P; Martin UJ; Newbold P
    Lancet Respir Med; 2020 Feb; 8(2):158-170. PubMed ID: 31575508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute Blood Eosinophil Counts to Guide Inhaled Corticosteroids Therapy Among Patients with COPD: Systematic Review and Meta-analysis.
    Oshagbemi OA; Odiba JO; Daniel A; Yunusa I
    Curr Drug Targets; 2019; 20(16):1670-1679. PubMed ID: 31393244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blood eosinophils as a biomarker of future COPD exacerbation risk: pooled data from 11 clinical trials.
    Singh D; Wedzicha JA; Siddiqui S; de la Hoz A; Xue W; Magnussen H; Miravitlles M; Chalmers JD; Calverley PMA
    Respir Res; 2020 Sep; 21(1):240. PubMed ID: 32943047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma.
    Shimoda T; Odajima H; Okamasa A; Kawase M; Komatsubara M; Mayer B; Yancey S; Ortega H
    Allergol Int; 2017 Jul; 66(3):445-451. PubMed ID: 28110896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blood Eosinophil Counts, Withdrawal of Inhaled Corticosteroids and Risk of COPD Exacerbations and Mortality in the Clinical Practice Research Datalink (CPRD).
    Oshagbemi OA; Franssen FME; van Kraaij S; Braeken DCW; Wouters EFM; Maitland-van der Zee AH; Driessen JHM; de Vries F
    COPD; 2019 Apr; 16(2):152-159. PubMed ID: 31117850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.
    Watz H; Tetzlaff K; Wouters EF; Kirsten A; Magnussen H; Rodriguez-Roisin R; Vogelmeier C; Fabbri LM; Chanez P; Dahl R; Disse B; Finnigan H; Calverley PM
    Lancet Respir Med; 2016 May; 4(5):390-8. PubMed ID: 27066739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood eosinophil count, a marker of inhaled corticosteroid effectiveness in preventing COPD exacerbations in post-hoc RCT and observational studies: systematic review and meta-analysis.
    Harries TH; Rowland V; Corrigan CJ; Marshall IJ; McDonnell L; Prasad V; Schofield P; Armstrong D; White P
    Respir Res; 2020 Jan; 21(1):3. PubMed ID: 31900184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exacerbation Frequency And Eosinophil Counts Among Patients With COPD Currently Prescribed Triple Therapy.
    Benson VS; Pascoe KC; Siddall J; Small M; Müllerová H
    Int J Chron Obstruct Pulmon Dis; 2019; 14():2711-2723. PubMed ID: 31819403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of Blood Eosinophil Count to Exacerbations in Chronic Obstructive Pulmonary Disease.
    Zeiger RS; Tran TN; Butler RK; Schatz M; Li Q; Khatry DB; Martin U; Kawatkar AA; Chen W
    J Allergy Clin Immunol Pract; 2018; 6(3):944-954.e5. PubMed ID: 29153881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility.
    Humbert M; Albers FC; Bratton DJ; Yancey SW; Liu MC; Hozawa S; Llanos JP; Kwon N
    Respir Med; 2019; 154():69-75. PubMed ID: 31220806
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid and Consistent Improvements in Morning PEF in Patients with Severe Eosinophilic Asthma Treated with Mepolizumab.
    Ortega H; Menzies-Gow A; Llanos JP; Forshag M; Albers F; Gunsoy N; Bradford ES; Yancey SW; Kraft M
    Adv Ther; 2018 Jul; 35(7):1059-1068. PubMed ID: 29949045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.
    Pascoe S; Locantore N; Dransfield MT; Barnes NC; Pavord ID
    Lancet Respir Med; 2015 Jun; 3(6):435-42. PubMed ID: 25878028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial.
    Yousuf AJ; Mohammed S; Carr L; Yavari Ramsheh M; Micieli C; Mistry V; Haldar K; Wright A; Novotny P; Parker S; Glover S; Finch J; Quann N; Brookes CL; Hobson R; Ibrahim W; Russell RJ; John C; Grimbaldeston MA; Choy DF; Cheung D; Steiner M; Greening NJ; Brightling CE
    Lancet Respir Med; 2022 May; 10(5):469-477. PubMed ID: 35339234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benralizumab for the Prevention of COPD Exacerbations.
    Criner GJ; Celli BR; Brightling CE; Agusti A; Papi A; Singh D; Sin DD; Vogelmeier CF; Sciurba FC; Bafadhel M; Backer V; Kato M; Ramírez-Venegas A; Wei YF; Bjermer L; Shih VH; Jison M; O'Quinn S; Makulova N; Newbold P; Goldman M; Martin UJ; ;
    N Engl J Med; 2019 Sep; 381(11):1023-1034. PubMed ID: 31112385
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.